secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001600620-23-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q3 net product revenue $40.8M (+60% YoY); narrows FY2023 guidance to $155-160M
--------------------------------------------------------------------------------

- Net product revenue $40.8M in Q3, up 60% YoY; 9-month net product revenue $116.2M (+55%).
- Narrowed FY2023 net product revenue guidance to $155-160M from prior range.
- Net loss $13.4M ($0.09/share) vs $9.0M ($0.06/share) in Q3 2022; 9-month net loss improved to $51.1M from $82.1M.
- Patients on LUPKYNIS at Sept 30: ~1,939 (+43% YoY); 436 PSFs added in Q3 (+17%).
- Received $10M milestone from Otsuka for European pricing and reimbursement in three major markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000043/0001600620-23-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000043/auph-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001600620-23-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer